RDNT RadNet Earnings Preview May 10, 2026

RadNet, Inc. (RDNT) will report earnings on May 10, 2026 after market close. Analysts expect the diagnostic imaging company to post an EPS of -$0.1643 and revenue of $557.93 million. This earnings preview matters because RadNet’s recent performance has been mixed, with the stock down 19.4% year-to-date. The company operates over 347 imaging centers across the United States and is investing heavily in AI-powered diagnostic tools. Understanding what to expect helps investors prepare for potential market moves.

Earnings Estimates vs. Historical Performance

RadNet’s earnings preview shows analysts expect a loss this quarter, marking a shift from recent profitability. The -$0.1643 EPS estimate contrasts sharply with the company’s recent beat pattern.

Recent Earnings Track Record

Looking at the last four quarters, RadNet has delivered mixed results. In Q3 2026 (March earnings), the company beat EPS expectations by posting $0.23 actual versus $0.19 estimated. Revenue came in at $547.7 million versus $550.2 million estimated, a slight miss. The previous quarter showed stronger performance with $0.31 actual EPS against $0.17 estimated, a significant beat. However, Q1 2026 revealed weakness with -$0.35 actual EPS versus -$0.17 estimated, a substantial miss. This pattern suggests earnings volatility.

Revenue Trend Analysis

Revenue estimates of $557.93 million represent growth from recent quarters. Q3 2026 revenue was $547.7 million, so the current estimate implies 1.9% sequential growth. The company has shown consistent revenue expansion over the past year, growing from $471.4 million in Q1 2026 to current levels. This 18.3% year-over-year growth demonstrates the company’s ability to expand its imaging center network and increase patient volume.

What Analysts Expect and Key Metrics

Wall Street consensus on RadNet remains cautiously optimistic despite near-term earnings challenges. The company carries a consensus rating of 4.0 out of 5, with 2 Strong Buy and 8 Buy ratings from analysts. This bullish stance reflects confidence in RadNet’s long-term strategy.

Profitability and Cash Flow Concerns

The negative EPS estimate signals ongoing profitability challenges. RadNet’s trailing twelve-month net income per share stands at -$0.25, indicating the company is currently unprofitable. However, operating cash flow remains positive at $3.97 per share, suggesting the business generates cash despite accounting losses. Free cash flow is negative at -$2.37 per share, reflecting significant capital expenditures on imaging equipment and facility expansion. This investment posture is typical for growth-stage healthcare companies.

Valuation and Market Position

At $57.50 per share, RadNet trades at a price-to-sales ratio of 2.19x, which is reasonable for a healthcare services company. The $4.5 billion market cap positions RadNet as a mid-cap player in diagnostic imaging. Meyka AI rates RDNT with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Beat or Miss Prediction and What to Watch

Based on RadNet’s recent earnings pattern, investors should prepare for potential volatility. The company has shown an ability to beat on EPS in strong quarters but has also delivered significant misses.

Historical Beat/Miss Pattern

RadNet beat EPS expectations in two of the last four quarters, with one significant beat (+$0.14 in Q3 2026) and one major miss (-$0.18 in Q1 2026). Revenue misses have been modest. This suggests the company’s profitability is more volatile than revenue generation. The current negative EPS estimate may be conservative, given recent operational improvements. However, the company’s path to profitability remains uncertain.

Key Metrics to Monitor

Investors should focus on several critical areas during the earnings call. Imaging center utilization rates indicate whether patient volume is growing. Same-center revenue growth shows organic expansion versus acquisition-driven growth. Operating margin trends reveal whether the company is improving operational efficiency. Capital expenditure guidance signals management’s confidence in future growth. AI product adoption metrics matter because RadNet is investing heavily in AI-powered diagnostic tools for mammography, lung cancer, and prostate cancer detection. Management commentary on reimbursement rates and insurance coverage will also influence the stock’s post-earnings direction.

Technical Setup and Stock Momentum

RadNet’s technical picture shows mixed signals heading into earnings. The stock has declined 1.94% in the past day but is up 5.35% over the past month, suggesting recent recovery momentum.

Price Action and Support Levels

The stock trades near its 50-day moving average of $60.32, indicating it’s slightly below intermediate support. The 200-day moving average sits at $69.49, showing the stock remains below longer-term trend resistance. Year-to-date performance of -19.4% reflects sector-wide pressure on healthcare services stocks. However, the 52-week range of $50.76 to $85.84 shows the stock has recovered from lows but remains well below highs.

Momentum Indicators

The RSI of 47.12 suggests neutral momentum, neither overbought nor oversold. The MACD histogram of 0.32 is positive but weak, indicating early bullish momentum. Volume has been solid at 896,076 shares versus the average of 834,781, showing investor interest. These technical factors suggest the stock could move sharply on earnings results, with potential for both upside and downside surprises.

Final Thoughts

RadNet faces a critical earnings moment. Despite expected near-term losses, strong revenue growth and a 4.0 analyst consensus suggest confidence in management’s strategy. Key metrics to watch include imaging center utilization, same-center growth, and AI adoption. With a B grade from Meyka AI, RadNet shows potential but must demonstrate a path to consistent profitability. The earnings report will reveal whether the company can overcome current headwinds or faces continued challenges.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.